Overview

BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to evaluate the efficacy and safety of BPDO-1603 in patients with moderate-to-severe Alzheimer's disease
Phase:
Phase 3
Details
Lead Sponsor:
Hyundai Pharmaceutical Co., LTD.